Merck stock climbs on melanoma trial data and a $368.94 billion valuation
Published on 08/30/2026 at 16:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co., Inc. (ISIN US58933Y1055) is back in the spotlight after new melanoma trial data tied to its cancer program, while the shares were quoted at $148.30 and down 0.80% in the latest market snapshot.
The same quote page put Merck's market capitalization at $368.94 billion, with a previous close of $149.54 and a 52-week range of $77.58 to $156.92 as of August 30, 2026.
Trial data drives the tape
Fresh reporting on August 30, 2026 said Merck and Moderna disclosed the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The study covered stage IIB to IV melanoma after surgery, a setting where KEYTRUDA is already widely used.
That matters because the market is not just reacting to a single headline result. It is also reassessing how a therapy with Phase 3 momentum could widen the long runway for Merck's oncology franchise, which already sits at the center of the company's growth story.
What the latest numbers say
The most recent market data in this call showed Merck at $148.30, while the previous close stood at $149.54 and the one-year band stretched from $77.58 to $156.92. The valuation backdrop is still elevated, with a market cap of $368.94 billion.
A separate market snapshot put the stock at $148.30, a 50-day moving average of $131.78 and a 200-day moving average of $122.41. That means the shares were trading 12.6% above the 50-day line and 21.0% above the 200-day line, a useful sign that the chart still reflects a strong prior run.
Why investors care
Merck's cancer portfolio remains the key lens for investors because KEYTRUDA is already a major commercial anchor, and any validated expansion in melanoma or adjacent tumor settings could deepen that franchise. The new Phase 3 readout also gives the stock a concrete catalyst beyond routine portfolio noise.
Merck shares are listed on the NYSE under MRK, and the latest market snapshot also showed a beta of 0.19 and a P/E ratio of 118.64. For a large-cap pharma name, that mix points to a market that is still paying for pipeline optionality as much as for current earnings.
Keytruda still matters
KEYTRUDA remains Merck's best-known product and the commercial center of its oncology business. The melanoma data matter because they add another layer to a franchise that already spans immunotherapy, combination therapy and multiple tumor types.
Merck stock level
Merck stock traded at $148.30 as of August 28, 2026, in the latest quote snapshot, with the market closed and the one-year high at $156.92.
Company
Company: Merck & Co., Inc.
ISIN: US58933Y1055
Ticker: MRK
Exchange: NYSE
Price (as of August 28, 2026): $148.30 USD
Market cap: $368.94 billion (as of August 30, 2026)
Sector / Industry: Health Care / Pharmaceuticals
Index membership: Dow Jones Industrial Average
Next earnings date: November 6, 2026
More on Merck stock
More on Merck stock: the company's oncology pipeline and KEYTRUDA remain the central drivers behind investor interest.
